Merck's Investigational Migraine Treatment Telcagepant Improved Pain And Migraine-Associated Symptoms In Phase III Study Merck & Co., Inc. announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo.
Source: www.medicalnewstoday.comSenate Veterans' Affairs Committee Approves Bill That Would Improve Female Veterans' Health Care The Senate Veterans' Affairs Committee on Thursday approved by voice vote legislation that would improve
health care for female veterans, the Tacoma News Tribune reports. The bill (
Source: www.medicalnewstoday.comScottish Government To Provide No-Cost EC At Most Community Pharmacies The Scottish government plans to provide no-cost emergency contraception at most of the country's 1,200 community pharmacies, Scottish Public
Health Minister Shona Robison announced Wednesday, the Scotsman reports. Robison said that she hopes by making the services part of the national contract with pharmacies, women will receive increased access to EC.
Source: www.medicalnewstoday.com
# posted by Network @ 11:00 AM
